FGF4 alleviates the lung cell damage caused by high glucose via AMPK‑PGC‑1 signaling axis in vitro and in vivo

Qiujuan Fu, Yongfang Ou, Qin Wu, Jue Gong, Faxin Li, Tuxing Wang, Lin Zeng, Kejie Huang, Jianlong XieInternational Journal of Molecular Medicine 2025 · DOI

TL;DR

This study reveals that fibroblast growth factor 4 (FGF4) can protect lung cells from damage caused by high glucose, a common complication of diabetes. FGF4 achieves this by activating the AMPK-PGC-1 signaling pathway, which helps reduce inflammation, oxidative stress, and fibrosis in lung tissues. This finding offers a promising new therapeutic avenue for treating diabetes-related lung injury.

What Problem Does This Paper Address?

Diabetes, a chronic metabolic disorder, is associated with a wide range of complications, including damage to the lungs. Long-term hyperglycemia can lead to pulmonary microvascular disease and neural regulation disorders, resulting in structural and functional abnormalities in the lungs. These "diabetes-related lung injuries" can manifest as interstitial lung disease, characterized by inflammation, oxidative stress, and fibrosis, and often go unnoticed in the early stages. Current treatments for these lung complications are limited, highlighting the need for novel therapeutic strategies. This paper investigates the potential of fibroblast growth factor 4 (FGF4) as a protective agent against high-glucose-induced lung damage.

Methods

The researchers employed a multi-faceted approach to investigate FGF4's effects, both in cell cultures and in animal models:

  • In vitro studies:
    • Cell lines: Murine alveolar epithelial cells (MLE-12) and human bronchial epithelial cells (BEAS-2B) were used to mimic lung tissue.
  • High-glucose model: Cells were exposed to high glucose concentrations (30 mmol/l) to induce damage.
  • FGF4 treatment: Various concentrations of FGF4 (10, 50, and 100 ng/ml) were applied to assess its protective effects.
  • Biochemical Assays: * CCK-8 assay: To measure cell proliferation and viability.
  • Western blotting: To quantify the expression levels of key proteins involved in cell cycle regulation (CyclinD1, PCNA, p21, p53), inflammation (IL-6, IL-1β, p-IκB, p-P65, p-STAT3), fibrosis (FN1, α-SMA, E-cadherin, N-cadherin), autophagy (LC3-II, p62), and signaling pathways (PGC-1, TFAM, AMPK, p-AMPK, cGAS, STING, p-STING, NF-κB, p-NF-κB).
  • Immunohistochemistry and Immunofluorescence: To visualize the localization and expression of specific proteins and inflammatory markers (TNF-α, IL-1β, IL-6, CD45, CD68, mtDNA, ROS, 4-HNE, 8-OHdG, SOD1, CAT) within cells and tissues.
  • Mitochondrial Assays: JC-1 staining and TMRE staining were used to assess mitochondrial membrane potential and autophagy.
  • siRNA: To specifically knock down AMPK to understand its role in FGF4's mechanism.
  • In vivo studies:
    • Diabetic Mouse Model: A type 1 diabetes model was established in C57BL/6J mice using streptozotocin (STZ) injections.
  • FGF4 Treatment: Diabetic mice were treated with FGF4 (0.5 and 1 mg/kg) via intraperitoneal injection.
  • Histological Analysis: Hematoxylin and eosin (H&E) staining and Masson trichrome staining were performed on lung tissues to assess structural changes, inflammation, and fibrosis.
  • Lung Function Tests: While not explicitly detailed as a separate method, the abstract mentions improved lung function in treated animals.

Datasets

Not discussed in the paper. The study relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • FGF4 as a Lung Protector: The most significant insight is that FGF4 can effectively mitigate high-glucose-induced damage to lung cells, both in vitro and in vivo. This suggests FGF4 has a direct protective role in the context of diabetes-related lung complications.
  • AMPK-PGC-1 Axis is Key: The study pinpoints the AMPK-PGC-1 signaling axis as the central mechanism through which FGF4 exerts its protective effects. This pathway is crucial for regulating cellular metabolism, antioxidant defense, and anti-inflammatory responses.
  • Mitophagy Matters: FGF4's ability to promote mitochondrial autophagy (mitophagy) is highlighted as a critical mechanism. By clearing damaged mitochondria, FGF4 prevents the release of inflammatory signals and maintains cellular health.
  • Broad Anti-Fibrotic and Anti-Inflammatory Effects: FGF4 not only protects against immediate cell damage but also reduces key markers of lung fibrosis and inflammation, suggesting a role in preventing long-term tissue remodeling and disease progression.
  • Potential for a New Therapeutic Strategy: The findings collectively propose FGF4 as a promising candidate for developing novel treatments for diabetes-related lung injuries, addressing a significant unmet clinical need.

Key Results

  • Cell Proliferation: FGF4 significantly increased the proliferation of lung cells damaged by high glucose, while suppressing cell cycle inhibitors like p21 and p53.
  • Inflammation Reduction: FGF4 treatment markedly decreased the expression of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and key signaling molecules in the NF-κB pathway (p-IκB, p-P65, p-STAT3) in both cell models and diabetic lung tissue.
  • Oxidative Stress Alleviation: FGF4 reduced reactive oxygen species (ROS) and malondialdehyde (MDA) levels, while increasing antioxidant enzyme expression (SOD1, CAT) in high-glucose-treated cells and diabetic lungs.
  • Fibrosis Mitigation: FGF4 treatment led to decreased expression of fibrosis markers (FN1, α-SMA, N-cadherin) and increased expression of an epithelial marker (E-cadherin) in lung tissues.
  • Mitochondrial Health: FGF4 promoted mitochondrial autophagy (mitophagy) and restored mitochondrial membrane potential in high-glucose-treated cells.
  • AMPK-PGC-1 Activation: FGF4 activated the AMPK-PGC-1 signaling pathway, which was shown to be essential for its protective effects, as inhibiting AMPK partially abolished FGF4's benefits.
  • In Vivo Efficacy: In diabetic mice, FGF4 treatment improved lung function, reduced lung inflammation and fibrosis, and lowered blood glucose levels.

Limitations and Future Work

The authors acknowledge several limitations and suggest future research directions:

  • Toxicological Studies: Comprehensive toxicological studies of FGF4 are needed to ensure its safety.
  • Targeting Specificity: Improving the targeting specificity of FGF4 to lung tissue is crucial, as it currently distributes to various organs.
  • Short Half-Life: The short half-life of FGF4 needs to be addressed, potentially through the development of nano-sustained release materials to prolong its therapeutic window and bioavailability.
  • Type 2 Diabetes Model: The current study used a type 1 diabetes model. Future research should evaluate FGF4's effects in type 2 diabetes models.
  • Insulin Control Group: The absence of an insulin control group in the in vivo experiments is noted as a limitation.
  • Nanomaterials: Developing lung-targeted nanomaterials is suggested as a strategy to enhance FGF4's efficacy.

Summary updated

Abstract

Long‑term hyperglycemia can damage the capillaries and neural regulation of the lungs, leading to pulmonary microvascular disease and neural regulation disorders, causing abnormalities in lung structure and function. The present study explored the effect of fibroblast growth factor (FGF)4 as a potential therapeutic growth factor on the effect of hyperglycemia on the lungs <i>in vitro</i> and <i>in vivo</i> models. The effect of FGF4 on the damage of lung cells caused by high glucose was evaluated <i>in vitro</i> and <i>in vivo</i> by a series of biochemical experiments (indirect immunofluorescence, western blotting, immunohistochemistry and siRNA). The results showed that FGF4 could effectively alleviate the inhibition of lung cell proliferation caused by high glucose. Further experiments found that high glucose caused inflammation, oxidative stress and fibrosis of lung cells, while the above pathological reactions were alleviated after treatment with FGF4. Further mechanism research showed that FGF4 treatment could markedly improve the survival rate of lung cells, reduce cell death and inflammatory responses and enhance the antioxidant stress resistance of cells. These effects are achieved by activating the adenosine monophosphate (AMP)‑activated protein kinase (AMPK)‑peroxisome proliferator‑activated receptor coactivator 1 (PGC‑1) signaling axis, which plays an important role in regulating cellular metabolism, antioxidant stress and anti‑inflammatory responses. <i>In vivo</i> experiments further confirmed the mitigating effect of FGF4 on lung tissue damage caused by high glucose. FGF4 treatment to diabetic model animals, lung function can be markedly improved and the degree of lung inflammation and fibrosis can be reduced. In summary, FGF4 exhibits a significant mitigating effect on high‑glucose‑induced lung cell damage through the AMPK‑PGC‑1 signaling axis, providing a new strategy for the treatment of diabetes and its pulmonary complications.
BibTeX
@article{fu2025fgf,
  author = {Qiujuan Fu and Yongfang Ou and Qin Wu and Jue Gong and Faxin Li and Tuxing Wang and Lin Zeng and Kejie Huang and Jianlong Xie},
  title = {{FGF4 alleviates the lung cell damage caused by high glucose via AMPK‑PGC‑1 signaling axis <i>in vitro</i> and <i>in vivo</i>}},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  doi = {10.3892/ijmm.2025.5710},
}
Figure